PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18824345-9 2009 The JNK inhibitor SP600125 inhibited basal and EGF-induced secretion of uPA, VEGF, MMP-9 and TIMP-1, as well as AP-1 DNA binding activity and cell migration. pyrazolanthrone 18-26 vascular endothelial growth factor A Homo sapiens 77-81 19553068-8 2009 TNF-alpha potently upregulated the mRNA and protein levels of VEGF, which were significantly reversed by JNK inhibitor SP600125. pyrazolanthrone 119-127 vascular endothelial growth factor A Homo sapiens 62-66 19026990-8 2009 TNF-alpha-induced VEGF expression was inhibited by SP600125 and U0126, which are inhibitors of JNK and MEK, respectively. pyrazolanthrone 51-59 vascular endothelial growth factor A Homo sapiens 18-22 17331500-9 2007 Moreover, TGF-beta2-induced RPE VEGF secretion was significantly reduced by inhibitors of mitogen-activated protein (MAP) kinase (MEK) (U0126), p38 (SB202190), c-Jun NH2-terminal kinase (JNK), Sp600125, protein tyrosine kinase (PTK) (Genistein), and phosphatidylinositol 3-kinase (PI3K) (Ly294002). pyrazolanthrone 193-201 vascular endothelial growth factor A Homo sapiens 32-36 17627770-9 2007 Selective inhibitors of p38 MAPK (SB203580), ERK (PD98059), and JNK (SP600125) could differentially inhibit the production of EGF, VEGF and CCL2, thereby suggesting a role for MAPKs in IL-31 functions. pyrazolanthrone 69-77 vascular endothelial growth factor A Homo sapiens 131-135 16932349-6 2006 Sp600125, an inhibitor of JNK activity and activator protein-1 (AP-1) binding to the VEGF promoter, downregulates the VEGF production without affecting Jak3 activity. pyrazolanthrone 0-8 vascular endothelial growth factor A Homo sapiens 85-89 16932349-6 2006 Sp600125, an inhibitor of JNK activity and activator protein-1 (AP-1) binding to the VEGF promoter, downregulates the VEGF production without affecting Jak3 activity. pyrazolanthrone 0-8 vascular endothelial growth factor A Homo sapiens 118-122 14602779-7 2003 The IGF-I-induced up-regulation of VEGF production was associated with activation of AP-1 and HIF-1 alpha and was abrogated by phosphatidylinositol 3-kinase inhibitors (wortmannin and LY294002); Jun kinase inhibitor (SP600125); HIF-1 alpha antisense oligonucleotide; or geldanamycin, an inhibitor of the heat shock protein 90 molecular chaperone, which regulates the three-dimensional conformation and function of IGF-I-receptor and Akt. pyrazolanthrone 217-225 vascular endothelial growth factor A Homo sapiens 35-39 16328781-6 2006 The VEGF mRNA induced by HBO was blocked by both PD98059 and SP600125, the ERK and JNK inhibitors respectively. pyrazolanthrone 61-69 vascular endothelial growth factor A Homo sapiens 4-8 14627919-0 2003 C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect. pyrazolanthrone 41-49 vascular endothelial growth factor A Homo sapiens 85-119 14627919-0 2003 C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect. pyrazolanthrone 41-49 vascular endothelial growth factor A Homo sapiens 121-125 14627919-5 2003 Thus, we tested the effect of a novel JNK inhibitor, SP600125, on VEGF production in fibroblasts. pyrazolanthrone 53-61 vascular endothelial growth factor A Homo sapiens 66-70 14627919-6 2003 SP600125 significantly suppressed interleukin (IL)-6-induced production of VEGF in cultured fibroblasts. pyrazolanthrone 0-8 vascular endothelial growth factor A Homo sapiens 75-79 14627919-9 2003 The results indicate that although both SP600125 and CsA are anti-angiogenic by inhibiting VEGF production by way of a JNK-dependent pathway, the inhibitory effect was much stronger with the novel inhibitor of JNK than with CsA. pyrazolanthrone 40-48 vascular endothelial growth factor A Homo sapiens 91-95 20463056-2 2010 VEGF-induced cell migration was blocked by specific kinase inhibitors of JNK1/2 (SP600125), c-Src (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine), and phosphatidylinositol 3-kinase/Akt (wortmannin) but not ERK2/1 (U0126) and p38MAPK (SB203580). pyrazolanthrone 81-89 vascular endothelial growth factor A Homo sapiens 0-4 32432052-7 2020 However, VEGF expression decreased after the pre-treatment with PI3K inhibitors (LY294002 and GDC-0941), ERK1/2 inhibitor (PD098059), and p38 MAPK inhibitor (SB203580), but not JNK inhibitor (SP600125), in a dose-dependent manner. pyrazolanthrone 192-200 vascular endothelial growth factor A Homo sapiens 9-13 23583400-10 2013 The IRE1 specific inhibitor irestatin, the JNK specific inhibitor SP600125, and the p38 MAPK specific inhibitor SB203580 significantly inhibited Ang II-induced capillary formation from endothelial cells and VEGF expression but had no effect on GRP78. pyrazolanthrone 66-74 vascular endothelial growth factor A Homo sapiens 207-211 22592917-4 2012 Further results showed that VEGFA induced the activation of JNK/SAPK, p38 kinase and extracellular signal-regulated kinases 1 and 2 (ERK1/2), while JNK/SAPK inhibitor SP600125 and specific siRNA both blocked all those angiogenic effects induced by VEGFA. pyrazolanthrone 167-175 vascular endothelial growth factor A Homo sapiens 28-33 22592917-6 2012 In addition, in vivo matrigel plug assay further showed that SP600125 inhibited VEGFA-induced angiogenesis. pyrazolanthrone 61-69 vascular endothelial growth factor A Homo sapiens 80-85 22592917-7 2012 Further results showed that SP600125 and JNK/SAPK siRNA decreased VEGFA-induced VEGFR2 (Flk-1/KDR) sustained phosphorylation in HUVECs. pyrazolanthrone 28-36 vascular endothelial growth factor A Homo sapiens 66-71 22110547-7 2012 In addition, EBNE-induced production of IL-6 and VEGF was inhibited by PD98059 (a p44/42 MAPK inhibitor), SB203580 (a p38 MAPK inhibitor), and PDTC (a NF-kappaB inhibitor), but not SP600125 (a JNK inhibitor). pyrazolanthrone 181-189 vascular endothelial growth factor A Homo sapiens 49-53 20876703-3 2010 The addition of an NO donor, Diethylenetriamine-NONOate, significantly activated expressions of MMP-9 and VEGF-A genes in breast carcinoma MDA-MD-231 cells and invasion of MDA-MB-231 cells in coculture with RAW264.7 macrophages as determined using Transwell systems, but that was inhibited by adding SP600125, BAY117082 and the nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester. pyrazolanthrone 300-308 vascular endothelial growth factor A Homo sapiens 106-112 29083089-7 2018 Furthermore, both U0126 (ErK inhibitor) and SP600125 (JNK inhibitor) significantly suppressed the enhanced production of HIF-1alpha and VEGF induced by HMGB1. pyrazolanthrone 44-52 vascular endothelial growth factor A Homo sapiens 136-140 28651835-8 2017 SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), reversed Andro-induced decrease in the expression of HIF-1alpha and VEGFA, but not MTA1 and HDAC1. pyrazolanthrone 0-8 vascular endothelial growth factor A Homo sapiens 125-130 27619643-5 2016 After CD147 stealth siRNA transfection treatment, the production of VEGF was reduced depended on the inhibition efficiency of CD147 siRNAs.The special signaling pathway inhibitors LY294002, SP600125, SB203580 and U0126 were added to cultures respectively and the results showed LY294002 dose-dependently inhibited the expression of VEGF. pyrazolanthrone 190-198 vascular endothelial growth factor A Homo sapiens 68-72 26098087-10 2015 The AM-induced increase in VEGF expression was significantly attenuated by SP600125, a specific JNK inhibitor. pyrazolanthrone 75-83 vascular endothelial growth factor A Homo sapiens 27-31 23428975-12 2013 Furthermore, Cav-1 increased proMMP-1 and VEGF secretion in HGFs, and the VEGF secretion was statistically suppressed by JNK inhibitor SP600125, but not ERK inhibitor PD98059. pyrazolanthrone 135-143 vascular endothelial growth factor A Homo sapiens 74-78